Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Research

High cortisol levels are associated with oxidative stress and mortality in maintenance hemodialysis patients

Authors: Juhee Kim, Kyu-sang Yun, Ajin Cho, Do Hyoung Kim, Young-Ki Lee, Myung-Jin Choi, Seok-hyung Kim, Hyunsuk Kim, Jong-Woo Yoon, Hayne C. Park

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Chronic stimulation of the mineralocorticoid receptor has been suggested as one of the potential causes of cardiovascular events and death in patients with end-stage renal disease. This observational cohort study was performed to demonstrate that serum cortisol might be a predictive marker for patient mortality and to evaluate its association with oxidized low-density lipoprotein (oxLDL) in hemodialysis (HD) patients.

Methods

Patients receiving HD three times a week were screened for enrollment at two institutions. Baseline cortisol levels were measured before each HD session, and the patients were divided into two groups according to the median value of serum cortisol before analysis. The baseline characteristics and laboratory values of the high and low cortisol groups were compared. Serum cortisol, adrenocorticotropic hormone, renin, aldosterone, and oxLDL were measured in 52 patients to evaluate the effect of oxidative stress on serum cortisol levels.

Results

A total of 133 HD patients were enrolled in this cohort study. Compared to the patients with low serum cortisol levels, the patients with high serum cortisol levels (baseline cortisol ≥ 10 μg/dL) showed higher rates of cardiovascular disease (59.7% vs. 39.4%, P=0.019) and left ventricular systolic dysfunction (LVSD) (25.9% vs. 8.0%, P=0.016). The patients in the high cortisol group demonstrated higher all-cause mortality than those in the low cortisol group. The serum cortisol level was an independent risk factor for patient mortality (hazard ratio 1.234, 95% confidence interval 1.022-1.49, P=0.029). Among the 52 patients with oxLDL measurements, oxLDL was an independent risk factor for elevated serum cortisol levels (Exp(B) 1.114, P=0.013) and LVSD (Exp(B) 12.308, P=0.045). However, plasma aldosterone levels did not affect serum cortisol levels.

Conclusions

Serum cortisol is a useful predictive marker for all-cause death among patients receiving HD. OxLDL is an independent marker for elevated serum cortisol among HD patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.CrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.CrossRef
2.
go back to reference Drechsler C, Ritz E, Tomaschitz A, Pilz S, Schonfeld S, Blouin K, et al. Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. Eur Heart J. 2013;34(8):578–87.CrossRef Drechsler C, Ritz E, Tomaschitz A, Pilz S, Schonfeld S, Blouin K, et al. Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. Eur Heart J. 2013;34(8):578–87.CrossRef
3.
go back to reference Catena C, Colussi G, Brosolo G, Novello M, Sechi LA. Aldosterone and Left Ventricular Remodeling. Horm Metab Res. 2015;47(13):981–6.CrossRef Catena C, Colussi G, Brosolo G, Novello M, Sechi LA. Aldosterone and Left Ventricular Remodeling. Horm Metab Res. 2015;47(13):981–6.CrossRef
4.
go back to reference Kritis AA, Gouta CP, Liaretidou EI, Kallaras KI. Latest aspects of aldosterone actions on the heart muscle. J Physiol Pharmacol. 2016;67(1):21–30.PubMed Kritis AA, Gouta CP, Liaretidou EI, Kallaras KI. Latest aspects of aldosterone actions on the heart muscle. J Physiol Pharmacol. 2016;67(1):21–30.PubMed
5.
go back to reference Grotevendt A, Wallaschofski H, Reincke M, Adolf C, Quinkler M, Nauck M, et al. Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry. Endocrine. 2017;57(2):298–307.CrossRef Grotevendt A, Wallaschofski H, Reincke M, Adolf C, Quinkler M, Nauck M, et al. Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry. Endocrine. 2017;57(2):298–307.CrossRef
6.
go back to reference Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999;12(9 Pt 1):867–73.CrossRef Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999;12(9 Pt 1):867–73.CrossRef
7.
go back to reference Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol. 2007;27(2):159–63.CrossRef Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol. 2007;27(2):159–63.CrossRef
8.
go back to reference Kohagura K, Higashiuesato Y, Ishiki T, Yoshi S, Ohya Y, Iseki K, et al. Plasma aldosterone in hypertensive patients on chronic hemodialysis: distribution, determinants and impact on survival. Hypertens Res. 2006;29(8):597–604.CrossRef Kohagura K, Higashiuesato Y, Ishiki T, Yoshi S, Ohya Y, Iseki K, et al. Plasma aldosterone in hypertensive patients on chronic hemodialysis: distribution, determinants and impact on survival. Hypertens Res. 2006;29(8):597–604.CrossRef
9.
go back to reference Hung SC, Lin YP, Huang HL, Pu HF, Tarng DC. Aldosterone and mortality in hemodialysis patients: role of volume overload. PLoS One. 2013;8(2):e57511.CrossRef Hung SC, Lin YP, Huang HL, Pu HF, Tarng DC. Aldosterone and mortality in hemodialysis patients: role of volume overload. PLoS One. 2013;8(2):e57511.CrossRef
10.
go back to reference Abd ElHafeez S, Tripepi G, Mallamaci F, Zoccali C. Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. Eur J Clin Invest. 2015;45(10):1077–86.CrossRef Abd ElHafeez S, Tripepi G, Mallamaci F, Zoccali C. Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. Eur J Clin Invest. 2015;45(10):1077–86.CrossRef
11.
go back to reference N'Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int. 2002;61(5):1859–66.CrossRef N'Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int. 2002;61(5):1859–66.CrossRef
12.
go back to reference Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53(2):286–90.CrossRef Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53(2):286–90.CrossRef
13.
go back to reference Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2(6):608–15.CrossRef Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2(6):608–15.CrossRef
14.
go back to reference Gracia-Iguacel C, Gonzalez-Parra E, Egido J, Lindholm B, Mahillo I, Carrero JJ, et al. Cortisol levels are associated with mortality risk in hemodialysis patients. Clin Nephrol. 2014;82(4):247–56.CrossRef Gracia-Iguacel C, Gonzalez-Parra E, Egido J, Lindholm B, Mahillo I, Carrero JJ, et al. Cortisol levels are associated with mortality risk in hemodialysis patients. Clin Nephrol. 2014;82(4):247–56.CrossRef
15.
go back to reference Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;21(1):120–3.CrossRef Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;21(1):120–3.CrossRef
16.
go back to reference Ansurudeen I, Pietzsch J, Graessler J, Ehrhart-Bornstein M, Saha S, Bornstein SR, et al. Modulation of adrenal aldosterone release by oxidative modification of low-density lipoprotein. Am J Hypertens. 2010;23(10):1061–8.CrossRef Ansurudeen I, Pietzsch J, Graessler J, Ehrhart-Bornstein M, Saha S, Bornstein SR, et al. Modulation of adrenal aldosterone release by oxidative modification of low-density lipoprotein. Am J Hypertens. 2010;23(10):1061–8.CrossRef
17.
go back to reference Toida T, Toida R, Yamashita R, Komiya N, Uezono S, Komatsu H, et al. Grading of Left Ventricular Diastolic Dysfunction with Preserved Systolic Function by the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations Contributes to Predicting Cardiovascular Events in Hemodialysis Patients. Cardiorenal Med. 2019;9(3):190–200.CrossRef Toida T, Toida R, Yamashita R, Komiya N, Uezono S, Komatsu H, et al. Grading of Left Ventricular Diastolic Dysfunction with Preserved Systolic Function by the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations Contributes to Predicting Cardiovascular Events in Hemodialysis Patients. Cardiorenal Med. 2019;9(3):190–200.CrossRef
18.
go back to reference Choi SR, Lee YK, Cho Park H, Kim DH, Cho A, Kang MK, et al. Clinical significance of central systolic blood pressure in LV diastolic dysfunction and CV mortality. PLoS One. 2021;16(5):e0250653.CrossRef Choi SR, Lee YK, Cho Park H, Kim DH, Cho A, Kang MK, et al. Clinical significance of central systolic blood pressure in LV diastolic dysfunction and CV mortality. PLoS One. 2021;16(5):e0250653.CrossRef
19.
go back to reference Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39 e14.CrossRef Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39 e14.CrossRef
20.
go back to reference Samouilidou EC, Karpouza AP, Kostopoulos V, Bakirtzi T, Pantelias K, Petras D, et al. E JG: Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail. 2012;34(2):160–4.CrossRef Samouilidou EC, Karpouza AP, Kostopoulos V, Bakirtzi T, Pantelias K, Petras D, et al. E JG: Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail. 2012;34(2):160–4.CrossRef
21.
go back to reference Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000;14(13):1996–2007.CrossRef Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000;14(13):1996–2007.CrossRef
22.
go back to reference Heeringa P, Tervaert JW. Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens. 2002;11(3):287–93.CrossRef Heeringa P, Tervaert JW. Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens. 2002;11(3):287–93.CrossRef
23.
go back to reference Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl. 1999;71:S51–3.CrossRef Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl. 1999;71:S51–3.CrossRef
24.
go back to reference Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267(2):536–40.CrossRef Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267(2):536–40.CrossRef
25.
go back to reference Waanders F, de Vries LV, van Goor H, Hillebrands JL, Laverman GD, Bakker SJ, et al. Aldosterone, from (patho) physiology to treatment in cardiovascular and renal damage. Curr Vasc Pharmacol. 2011;9(5):594–605.CrossRef Waanders F, de Vries LV, van Goor H, Hillebrands JL, Laverman GD, Bakker SJ, et al. Aldosterone, from (patho) physiology to treatment in cardiovascular and renal damage. Curr Vasc Pharmacol. 2011;9(5):594–605.CrossRef
26.
go back to reference Ledda A, Gonzalez M, Gulfo J, Diaz Ludovico I, Ramella N, Toledo J, et al. Decreased OxLDL uptake and cholesterol efflux in THP1 cells elicited by cortisol and by cortisone through 11beta-hydroxysteroid dehydrogenase type 1. Atherosclerosis. 2016;250:84–94.CrossRef Ledda A, Gonzalez M, Gulfo J, Diaz Ludovico I, Ramella N, Toledo J, et al. Decreased OxLDL uptake and cholesterol efflux in THP1 cells elicited by cortisol and by cortisone through 11beta-hydroxysteroid dehydrogenase type 1. Atherosclerosis. 2016;250:84–94.CrossRef
Metadata
Title
High cortisol levels are associated with oxidative stress and mortality in maintenance hemodialysis patients
Authors
Juhee Kim
Kyu-sang Yun
Ajin Cho
Do Hyoung Kim
Young-Ki Lee
Myung-Jin Choi
Seok-hyung Kim
Hyunsuk Kim
Jong-Woo Yoon
Hayne C. Park
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02722-w

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.